SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 1,087.66 |
| Enterprise Value ($M) | 1,182.08 |
| Book Value ($M) | 223.57 |
| Book Value / Share | 1.51 |
| Price / Book | 4.86 |
| NCAV ($M) | -26.59 |
| NCAV / Share | -0.18 |
| Price / NCAV | -40.91 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.44 |
| Return on Assets (ROA) | -0.30 |
| Return on Equity (ROE) | -0.63 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 3.38 |
| Current Ratio | 3.52 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 308.35 |
| Assets | 558.51 |
| Liabilities | 334.93 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Sumitomo Mitsui Trust Holdings, Inc. | |||
| 13G/A | Integrated Core Strategies (us) Llc | |||
| 13G/A | Matrix Capital Management Company, LP | 0.44 | -94.38 | |
| 13G | Rubric Capital Management LP | 9.76 | ||
| 13G/A | Vanguard Group Inc | 7.21 | 0.00 | |
| 13G | Nikko Asset Management Americas, Inc. | 5.24 | ||
| 13G/A | Viking Global Investors Lp | 20.70 | 0.00 | |
| 13G/A | ARK Investment Management LLC | 8.85 | 39.18 | |
| 13G | BlackRock, Inc. | 7.90 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 148,268 | 1,750,031 | 8.47 | |
| 114,473 | 865,467 | 13.23 | |
| 90,858 | 783,751 | 11.59 | |
| 104,413 | 687,548 | 15.19 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ACLX – Arcellx, Inc. | ACRS – Aclaris Therapeutics, Inc. |
| ACT – Enact Holdings, Inc. | AGIO – Agios Pharmaceuticals, Inc. |
| AKRO – Akero Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io